Fundraising FoxCaraway
acquired by Merck22 known investors
Find your way into Caraway
Sign up to see every warm intro you have to Caraway
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Caraway team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases. Acquired by Merck in 2023.
Investors · 22
How we know: Dementia Discovery Fund's portfolio page · Not right? Tell us
How we know: McCarthy Capital's portfolio page · prnewswire.com · Not right? Tell us
How we know: MRL Ventures Fund's portfolio page · Not right? Tell us
How we know: SV Health Investors's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
Also in the syndicate · 7
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AJun 2023 · 2 sources
GV (lead), Maveron (lead), 7wireVentures, Hopelab Ventures, Ingeborg Investments, OMERS Ventures, The Venture Collective, Wellington Access Ventures
Source ↗ - Undisclosed amountseed roundMay 2020
Bridge Investments, CompanyFirst, Five Four Ventures, G9 Ventures, Republic Labs, Springdale Ventures, Super Angel Syndicate, Wesray Social, WTI
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Caraway do?
- Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases. Acquired by Merck in 2023.
- Who are Caraway's investors?
- Caraway's investors include Dementia Discovery Fund, Eisai Innovation, Inc., McCarthy Capital, MRL Ventures Fund, SV Health Investors, AbbVie, Bridge Investments, Five Four Ventures and 7 more.
- Who acquired Caraway?
- Caraway was acquired by Merck.